CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $4.44 and traded as high as $6.95. CASI Pharmaceuticals shares last traded at $6.65, with a volume of 87,456 shares.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. HC Wainwright lowered their target price on CASI Pharmaceuticals from $12.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, May 15th. StockNews.com started coverage on shares of CASI Pharmaceuticals in a research note on Saturday. They set a “hold” rating for the company.
Get Our Latest Stock Analysis on CASI Pharmaceuticals
CASI Pharmaceuticals Stock Performance
CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.66). CASI Pharmaceuticals had a negative net margin of 105.76% and a negative return on equity of 110.11%. The business had revenue of $3.41 million during the quarter. As a group, sell-side analysts forecast that CASI Pharmaceuticals, Inc. will post -2.56 earnings per share for the current fiscal year.
Institutional Trading of CASI Pharmaceuticals
A hedge fund recently bought a new stake in CASI Pharmaceuticals stock. Howland Capital Management LLC purchased a new stake in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 40,429 shares of the biotechnology company’s stock, valued at approximately $146,000. Howland Capital Management LLC owned about 0.30% of CASI Pharmaceuticals as of its most recent SEC filing. Institutional investors own 22.23% of the company’s stock.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
Featured Articles
- Five stocks we like better than CASI Pharmaceuticals
- Using the MarketBeat Stock Split Calculator
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- How to Evaluate a Stock Before BuyingÂ
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What is Short Interest? How to Use It
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.